Q2 EPS Forecast for United Therapeutics Reduced by Analyst

United Therapeutics Co. (NASDAQ:UTHR - Free Report) - Equities research analysts at Zacks Research cut their Q2 2025 EPS estimates for United Therapeutics in a note issued to investors on Tuesday, May 20th. Zacks Research analyst R. Department now anticipates that the biotechnology company will post earnings per share of $6.23 for the quarter, down from their previous estimate of $6.71. The consensus estimate for United Therapeutics' current full-year earnings is $24.48 per share. Zacks Research also issued estimates for United Therapeutics' Q2 2026 earnings at $6.05 EPS, Q3 2026 earnings at $6.19 EPS, Q4 2026 earnings at $5.87 EPS, FY2026 earnings at $24.87 EPS, Q1 2027 earnings at $5.86 EPS and FY2027 earnings at $22.99 EPS.

UTHR has been the subject of several other reports. Bank of America raised shares of United Therapeutics from an "underperform" rating to a "neutral" rating and set a $314.00 target price for the company in a research report on Monday, April 21st. JPMorgan Chase & Co. reduced their price objective on shares of United Therapeutics from $355.00 to $350.00 and set an "overweight" rating for the company in a research note on Thursday, May 1st. Morgan Stanley boosted their price objective on shares of United Therapeutics from $346.00 to $348.00 and gave the stock an "equal weight" rating in a research note on Thursday, May 1st. Wall Street Zen cut shares of United Therapeutics from a "strong-buy" rating to a "buy" rating in a research note on Friday, May 2nd. Finally, HC Wainwright restated a "buy" rating and issued a $425.00 price objective on shares of United Therapeutics in a research note on Monday, May 5th. Four analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $392.00.

United Therapeutics Stock Down 0.3%

UTHR stock opened at $308.72 on Friday. The company has a market capitalization of $13.93 billion, a price-to-earnings ratio of 13.56, a P/E/G ratio of 0.97 and a beta of 0.58. United Therapeutics has a 12 month low of $264.33 and a 12 month high of $417.82. The firm has a 50 day moving average of $299.76 and a two-hundred day moving average of $338.84.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last posted its quarterly earnings results on Wednesday, April 30th. The biotechnology company reported $6.63 EPS for the quarter, topping the consensus estimate of $6.29 by $0.34. The business had revenue of $794.40 million during the quarter, compared to analysts' expectations of $726.82 million. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The firm's quarterly revenue was up 17.2% compared to the same quarter last year. During the same period last year, the company posted $6.17 earnings per share.

Institutional Investors Weigh In On United Therapeutics

Several large investors have recently made changes to their positions in UTHR. Wealthfront Advisers LLC grew its holdings in shares of United Therapeutics by 2,090,573.5% in the 4th quarter. Wealthfront Advisers LLC now owns 18,314,300 shares of the biotechnology company's stock worth $6,462,018,000 after purchasing an additional 18,313,424 shares during the last quarter. Norges Bank bought a new stake in shares of United Therapeutics in the 4th quarter worth about $151,764,000. FMR LLC grew its holdings in shares of United Therapeutics by 36.5% in the 4th quarter. FMR LLC now owns 1,471,405 shares of the biotechnology company's stock worth $519,170,000 after purchasing an additional 393,777 shares during the last quarter. Vaughan Nelson Investment Management L.P. bought a new stake in shares of United Therapeutics in the 1st quarter worth about $101,354,000. Finally, Nuveen LLC bought a new stake in shares of United Therapeutics in the 1st quarter worth about $83,533,000. Institutional investors own 94.08% of the company's stock.

Insider Activity at United Therapeutics

In other United Therapeutics news, COO Michael Benkowitz sold 10,000 shares of the business's stock in a transaction on Monday, February 24th. The shares were sold at an average price of $360.76, for a total value of $3,607,600.00. Following the sale, the chief operating officer now owns 2,577 shares of the company's stock, valued at $929,678.52. The trade was a 79.51% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Paul A. Mahon sold 11,000 shares of the business's stock in a transaction on Thursday, April 17th. The shares were sold at an average price of $283.78, for a total transaction of $3,121,580.00. Following the completion of the sale, the executive vice president now directly owns 36,781 shares in the company, valued at $10,437,712.18. This trade represents a 23.02% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 55,500 shares of company stock worth $17,054,780 in the last ninety days. 10.30% of the stock is currently owned by insiders.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.